Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders

Kazuo Tamura, Akio Urabe, Minoru Yoshida, Akihisa Kanamaru, Yoshihisa Kodera, Shinichiro Okamoto, Shigefumi Maesaki, Tohru Masaoka

研究成果: Article査読

35 被引用数 (Scopus)

抄録

The study was conducted as a prospective multicenter trial to evaluate the efficacy and safety of micafungin in patients with invasive fungal infections (IFIs) in hematological disorders. A total of 277 patients was registered, and 197 were assessed for clinical efficacy. The mean dosage and duration of micafungin were 170.7 mg/day and 22.0 days, respectively. The efficacy rates were 87.5% (7/8) for patients with candidiasis, 44.7% (17/38) for probable IFIs, 61.9% (39/63) for possible IFIs and 80.7% (71/88) for those who failed to respond to antibacterials. In patients with febrile neutropenia (below 500 μL), despite broad-spectrum antibacterial treatment over 2 days, 86.3% (44/ 51) of patients had a favourable response to micafungin. The incidence of adverse events related to micafungin was 14.1% (39/277), but most of them were mild and reversible. These data indicate the usefulness of micafungin as a novel therapeutic drug for both empirical and targeted therapy for IFIs.

本文言語English
ページ(範囲)92-100
ページ数9
ジャーナルLeukemia and Lymphoma
50
1
DOI
出版ステータスPublished - 2009
外部発表はい

ASJC Scopus subject areas

  • 血液学
  • 腫瘍学
  • 癌研究

フィンガープリント

「Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル